Chinese TCM stocks surge; Jinghua Pharma hits limit up

The broad-based surge across multiple TCM names suggests a sector-wide catalyst rather than company-specific news, pointing to renewed investor appetite for traditional medicine themes. Jinghua Pharma's limit-up signals the strongest conviction, but the breadth of gainers indicates the move is systemic, potentially tied to policy shifts or market rotation. The key watchpoint is whether this momentum is sustained by fundamental drivers or fades as a short-term speculative wave. For market observers, the question is whether regulatory or industry developments underpin this rally, which would determine its durability.